Download PDF

1. Company Snapshot

1.a. Company Description

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers.


In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform.The company was founded in 2010 and is headquartered in New York, New York.

Show Full description

1.b. Last Insights on BYSI

The recent 3-month performance of BeyondSpring Inc. was negatively impacted by the company's decision to sell a portion of its equity interest in SEED Therapeutics for $35.4 million. This transaction, announced on January 28, 2025, resulted in BeyondSpring retaining approximately 14.4% of SEED's outstanding shares. Furthermore, SEED's lead asset RBM39 Degrader received Rare Pediatric Disease and Orphan Drug designations from the FDA, but the company's financials were not disclosed in the recent Form 10-K filing on March 27, 2025.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript)

Sep -15

Source: seekingalpha.com

Card image cap

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

Jul -07

Source: globenewswire.com

Card image cap

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

Jun -03

Source: globenewswire.com

Card image cap

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

May -12

Source: globenewswire.com

Card image cap

BeyondSpring Files 2024 Annual Report on Form 10-K

Mar -27

Source: globenewswire.com

Card image cap

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

Jan -28

Source: globenewswire.com

Card image cap

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

Jan -28

Source: globenewswire.com

Card image cap

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

Nov -11

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.70%)

6. Segments

Targeted Protein Degradation Platform

Expected Growth: 11.7%

BeyondSpring's Targeted Protein Degradation Platform growth is driven by increasing adoption in oncology and rare genetic disorders, strong pipeline of novel degraders, and partnerships with pharma companies. The 11.7% growth rate is also fueled by expanding research in protein degradation, growing demand for personalized medicine, and increasing investment in biotech R&D.

7. Detailed Products

Plinabulin

A novel, intravenous (IV) chemoprotective agent that has been shown to prevent chemotherapy-induced neutropenia (CIN) and increase the survival of cancer patients

Siplimab

A novel, humanized monoclonal antibody that targets CD47, a key immune checkpoint receptor

BeyondSpring Pipeline

A pipeline of novel, clinical-stage assets that target various types of cancer, including lung, breast, and pancreatic cancer

8. BeyondSpring Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

BeyondSpring Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and other diseases.

Bargaining Power Of Customers

BeyondSpring Inc. has a low bargaining power of customers due to the lack of negotiating power among patients and healthcare providers.

Bargaining Power Of Suppliers

BeyondSpring Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and services.

Threat Of New Entrants

BeyondSpring Inc. has a high threat of new entrants due to the growing demand for cancer treatments and the presence of emerging biotech companies.

Intensity Of Rivalry

BeyondSpring Inc. operates in a highly competitive industry with intense rivalry among established players and emerging companies.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight -17.51%
Debt Cost 3.95%
Equity Weight 117.51%
Equity Cost 5.53%
WACC 5.81%
Leverage -14.90%

11. Quality Control: BeyondSpring Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Puma Biotechnology

A-Score: 5.6/10

Value: 7.4

Growth: 6.1

Quality: 8.7

Yield: 0.0

Momentum: 9.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Ligand Pharmaceuticals

A-Score: 4.8/10

Value: 4.4

Growth: 4.4

Quality: 3.9

Yield: 0.0

Momentum: 10.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Ardelyx

A-Score: 3.8/10

Value: 6.8

Growth: 6.2

Quality: 4.7

Yield: 0.0

Momentum: 3.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
BeyondSpring

A-Score: 3.7/10

Value: 8.3

Growth: 5.8

Quality: 6.7

Yield: 0.0

Momentum: 0.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Y-mAbs Therapeutics

A-Score: 3.3/10

Value: 6.8

Growth: 7.3

Quality: 4.6

Yield: 0.0

Momentum: 0.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Applied Therapeutics

A-Score: 2.8/10

Value: 6.2

Growth: 6.9

Quality: 3.3

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.93$

Current Price

1.93$

Potential

-0.00%

Expected Cash-Flows